Tandem Diabetes Care’s (TNDM) Hold Rating Reaffirmed at Truist Financial

Truist Financial reaffirmed their hold rating on shares of Tandem Diabetes Care (NASDAQ:TNDM) in a research report report published on Monday morning, Marketbeat Ratings reports. They currently have a $27.00 price target on the medical device company’s stock, up from their prior price target of $24.00.

Several other research firms have also weighed in on TNDM. Wells Fargo & Company lifted their target price on Tandem Diabetes Care from $13.00 to $14.00 and gave the stock an “equal weight” rating in a report on Friday, November 7th. Piper Sandler reaffirmed a “neutral” rating and set a $21.00 price target (up previously from $14.00) on shares of Tandem Diabetes Care in a research report on Friday. Lake Street Capital upgraded Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $50.00 price objective on the stock in a report on Monday. Morgan Stanley set a $23.00 target price on Tandem Diabetes Care and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Tandem Diabetes Care in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Tandem Diabetes Care presently has a consensus rating of “Hold” and a consensus price target of $28.00.

Tandem Diabetes Care Stock Performance

Shares of NASDAQ:TNDM opened at $28.26 on Monday. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of -9.21 and a beta of 1.68. The firm’s 50 day simple moving average is $21.04 and its 200 day simple moving average is $17.16. The company has a debt-to-equity ratio of 2.00, a current ratio of 2.55 and a quick ratio of 2.02. Tandem Diabetes Care has a fifty-two week low of $9.98 and a fifty-two week high of $35.12.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its earnings results on Thursday, February 19th. The medical device company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.04. The firm had revenue of $290.38 million during the quarter, compared to the consensus estimate of $277.14 million. Tandem Diabetes Care had a negative net margin of 20.17% and a negative return on equity of 68.23%. The business’s quarterly revenue was up 15.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.01 earnings per share. As a group, sell-side analysts forecast that Tandem Diabetes Care will post -1.68 earnings per share for the current year.

Hedge Funds Weigh In On Tandem Diabetes Care

Several hedge funds have recently made changes to their positions in TNDM. Smartleaf Asset Management LLC increased its stake in shares of Tandem Diabetes Care by 80.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,330 shares of the medical device company’s stock worth $30,000 after purchasing an additional 593 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in Tandem Diabetes Care by 200.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,205 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 1,470 shares during the last quarter. CWM LLC grew its holdings in Tandem Diabetes Care by 262.6% during the second quarter. CWM LLC now owns 2,796 shares of the medical device company’s stock worth $52,000 after purchasing an additional 2,025 shares during the period. Van ECK Associates Corp increased its position in Tandem Diabetes Care by 67.4% during the fourth quarter. Van ECK Associates Corp now owns 3,430 shares of the medical device company’s stock worth $75,000 after buying an additional 1,381 shares during the last quarter. Finally, Creative Financial Designs Inc. ADV raised its stake in Tandem Diabetes Care by 36.0% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 3,431 shares of the medical device company’s stock valued at $75,000 after buying an additional 909 shares during the period.

Tandem Diabetes Care News Roundup

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Q4 execution — Company beat on revenue and posted better-than-expected EPS in the latest quarter, with management signaling solid operational execution that underpins today’s buying interest. Article Title
• Positive Sentiment: Analyst action — Truist reaffirmed a “hold” but raised its price target (from $24 to $27), a modest vote of confidence that likely supported upside after the earnings beat. Article Title
• Neutral Sentiment: Company filing — Tandem confirmed it intends to privately place $200M aggregate principal of convertible senior notes due 2032 to qualified institutional buyers; terms/convertibility details and timing are subject to market conditions. This is a factual disclosure that creates financing optionality but also potential dilution risk. Article Title
• Neutral Sentiment: Earnings-call takeaways — Management signaled a strategic shift (pay-as-you-go transition and other initiatives) that investors should monitor for margin and cash-flow implications; these are longer-term operational items rather than immediate catalysts. Article Title
• Negative Sentiment: Convertible-debt market reaction — Media coverage and traders reacted negatively to the $200M convertible offering announcement, citing dilution and financing concerns; several wires reported immediate selling pressure after the news. Article Title
• Negative Sentiment: Institutional selling & flows — Reports that the Brown Capital Management Small Company Fund sold its TNDM position likely amplified volatility and contributed to near-term selling pressure. Article Title
• Negative Sentiment: Mixed analyst/target moves — Other published price-target notes are below current trading levels (e.g., a $22 target reported by some outlets), reinforcing mixed expectations and adding to intraday selling dynamics. Article Title

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.